Medically reviewed by a specialist in nuclear medicine oncology. Last reviewed: June 2026.

Fertility, Pregnancy, and Lu-177 DOTATATE: What Young Patients with Neuroendocrine Tumors Should Know Before Starting PRRT

This article is for patients on the Lu-177 DOTATATE (PRRT) track - specifically those with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and other somatostatin receptor-positive NETs. If you are here about prostate cancer, the Lu-177 PSMA track covers your treatment.

If you are in your 20s, 30s, or early 40s and your oncologist has recommended lutetium Lu-177 dotatate (the drug sold as Lutathera), you may be wondering: what does this treatment mean for my ability to have children? This is an important question, and it deserves a clear answer before your first infusion.

PRRT (peptide receptor radionuclide therapy) works by delivering targeted radiation to NETs through a carrier molecule that targets somatostatin receptors on tumor cells. That radiation is precise. But it doesn't stay only in the tumor. Some reaches nearby healthy tissue. Some leaves the body through urine. This systemic exposure creates the reproductive health concerns in this article.

What Happens in Your Body During PRRT?

Lutetium Lu-177 dotatate (Lutathera) is a radioligand - a carrier molecule bonded to a radioactive atom. The carrier, dotatate, binds to somatostatin receptors that many NETs express in high numbers. Once bound, lutetium-177 emits short-range beta radiation directly at the tumor cell.

You can read a detailed explanation in our guide on how Lu-177 DOTATATE targets somatostatin receptors. For fertility purposes, the key point is this: while most radiation goes to the tumor, some circulates through the body and leaves via the kidneys and urinary tract. This systemic exposure creates the reproductive considerations below.

Can PRRT Affect Your Fertility?

The honest answer: it might. The FDA prescribing information for Lutathera states that patients must be informed of the potential for gonadal toxicity with this treatment. Large clinical trials have not specifically tracked long-term fertility outcomes in young NET patients after PRRT. What is known comes from the drug label and research.

For women, research shows that even modest radiation doses in the ovarian region may affect the pool of available eggs. A review of radiation effects on female fertility published in NIH/PMC noted that radiation exposure to the ovarian area may reduce the follicle reserve. How much dose reaches the ovaries during PRRT depends on tumor location, number of treatment cycles, and your anatomy. Your nuclear medicine team can estimate this through dosimetry for your case.

For men, the Lutathera label states that lutetium Lu-177 dotatate can cause lower sperm counts and may affect the ability to father a child. The effect on sperm production may be temporary or longer depending on the radiation dose.

Neither outcome is certain. But they are both possible and worth discussing with your team before treatment starts.

What Does the FDA Require About Contraception During and After PRRT?

The contraception requirements in the Lutathera label are specific. According to the FDA prescribing information:

• Women of reproductive potential must use effective contraception during treatment and for 7 months after the last dose.
• Men with female partners of reproductive potential must use effective contraception during treatment and for 4 months after the last dose.
• A negative pregnancy test must be confirmed within 7 days before starting treatment for all women of reproductive potential.

The label also makes a point that often surprises patients: even if your menstrual cycle becomes irregular or stops during treatment, or if you believe you may not be producing sperm, you could still be fertile. Do not assume that treatment-related changes mean you are protected. Effective contraception means a method with less than a 1% failure rate per year when used correctly. Your care team can advise which method suits your situation and medical history.

What Are the Risks if You Become Pregnant During or Shortly After PRRT?

Lutetium Lu-177 dotatate can cause serious harm to a developing fetus. The FDA label is direct about this. Ionizing radiation is one of the best-studied causes of fetal tissue damage, especially in early development. If you think you may have become pregnant during treatment or within the contraception window, contact your oncologist right away.

Radiation leaves the body in urine after each cycle. Partners of male patients who have recently received PRRT should avoid prolonged close contact in the days after treatment, following standard radiation safety guidance. Your nuclear medicine team will give you specific written instructions.

Don't breastfeed during PRRT or for at least 2.5 months after the last dose. We don't yet know whether lutetium Lu-177 dotatate passes into breast milk. Because the potential risk to a nursing infant is serious, the label advises against breastfeeding during this window. If you are breastfeeding when PRRT is recommended, discuss timing with your oncologist before your first cycle.

Your Fertility Preservation Options Before Starting

If you want to keep your options open for having children after PRRT, start before your first cycle. Fertility preservation takes time to arrange. Talk to your oncologist early to learn what options are available to you.

For women

• Egg freezing (oocyte cryopreservation): Doctors retrieve eggs after a short hormonal stimulation and store them frozen. This is the most established option for women without a partner or who don't want to create embryos. The process usually takes 10 to 14 days. Your oncology team and fertility clinic should work together so cancer treatment doesn't get delayed.
• Embryo freezing: If you have a partner, you can store fertilized embryos instead. Frozen embryo transfer has strong success rates.
• Ovarian tissue cryopreservation: Available at some specialized centers, this involves removing and freezing part of ovarian tissue before treatment, which doctors can re-implant later. It's more complex and not available everywhere, but ask about it if you can't do egg or embryo freezing in time.

For men

• Sperm banking: Doctors collect, analyze, and freeze a semen sample before treatment begins. The FDA label for Lutathera specifically says patients should discuss sperm freezing with their care team before starting. This usually takes a few days and can be done at most fertility clinics or urology centers.

Clinical guidance on fertility preservation in cancer patients available through NIH/PMC recommends that oncologists and fertility specialists work together in planning before cancer treatment begins. You have the right to ask for this coordinated approach.

When Can You Safely Try to Conceive After Completing PRRT?

Based on the FDA label, the minimum waiting periods after your last dose of Lutathera before trying to have a baby are 7 months for women and 4 months for men (meaning their female partners). In practice, many doctors recommend waiting longer - to make sure the tumor is stable and the body has recovered.

The Lutathera label also recommends talking with a genetics specialist if you wish to have children after PRRT, because ionizing radiation might affect genetic material in reproductive cells. A genetics specialist can discuss your individual risk in detail. If you froze eggs, embryos, or sperm before treatment, those samples can stay stored for years while you wait.

What the NETTER-1 Evidence Means for a Young Patient

Understanding the evidence behind PRRT helps put the fertility conversation in context. The landmark NETTER-1 phase 3 trial, published in the New England Journal of Medicine, found that lutetium Lu-177 dotatate gave patients much longer progression-free survival compared with high-dose octreotide LAR in people with advanced midgut NETs. About 18% of patients in the lutetium group had tumor responses. Later follow-up analyses of NETTER-1 data show median progression-free survival of about 28 to 33 months for patients treated with lutetium Lu-177 dotatate.

For a young patient, this context matters. PRRT may offer good disease control for months or years. The fertility conversation is not about whether to get treatment. It's about making sure your treatment plan protects your future along with your health today.

Before starting treatment, you'll need specific blood tests and imaging to confirm you are eligible. Our guide to lab results and scans required before Lu-177 DOTATATE for well-differentiated NETs covers the pre-treatment workup in detail.

How to Talk to Your Care Team About Fertility

Raising fertility questions in a cancer consultation can feel difficult. But your care team needs to know your priorities so they can work with you, not just around you. These are questions to ask before starting PRRT:

• How much radiation dose is likely to reach my ovaries or testes during my treatment course?
• Is there time for me to see a fertility specialist before I start, or is there clinical urgency to begin soon?
• Can you refer me to a reproductive endocrinologist and a genetics counselor?
• Which contraception method is safest for me given my medical history?
• What radiation safety precautions should my partner follow in the days after each cycle?

The FDA label for Lutathera requires doctors to tell patients about the potential for gonadal toxicity and to discuss fertility preservation options before treatment. If this conversation hasn't happened in your consultations yet, you can ask for it directly. For more about what to arrange in the weeks before your first infusion, see our article on preparing for your first Lu-177 DOTATATE infusion.

Key Timelines at a Glance

This timeline summarizes the time-specific requirements from the FDA prescribing information for lutetium Lu-177 dotatate (Lutathera). Use this as a reference when planning with your care team:

• Before treatment starts: Negative pregnancy test required (women). Discuss egg freezing, embryo freezing, or sperm banking with your oncologist and a fertility specialist.
• During treatment: Effective contraception required for both women and men. No breastfeeding.
• After last dose - women: Continue contraception for at least 7 months. No breastfeeding for at least 2.5 months.
• After last dose - men: Use contraception with any female partner for at least 4 months.
• Before trying to conceive: Request a genetics consultation. Discuss your individual timeline with your oncologist based on your response and disease stability.

If you have a Ga-68 DOTATATE-PET scan confirming somatostatin receptor expression and are considering PRRT as your next step, you can send your imaging and recent reports to HealthUnwired for a free eligibility review. If lutetium Lu-177 dotatate isn't right for your case now, you can also get a second opinion on other options.

When to Talk to Your Doctor

Talk to your oncologist about fertility before your first PRRT infusion, not after. Ask specifically for referrals to a reproductive endocrinologist and a genetics counselor as part of your pre-treatment planning. If you're already getting treatment and this conversation hasn't happened yet, you can still bring it up at your next appointment. Your team may be able to help you.

This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.